These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 458200

  • 1. Simultaneous administration of live, enteric-coated adenovirus types 4, 7 and 21 vaccines: safety and immunogenicity.
    Takafuji ET, Gaydos JC, Allen RG, Top FH.
    J Infect Dis; 1979 Jul; 140(1):48-53. PubMed ID: 458200
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults.
    Lyons A, Longfield J, Kuschner R, Straight T, Binn L, Seriwatana J, Reitstetter R, Froh IB, Craft D, McNabb K, Russell K, Metzgar D, Liss A, Sun X, Towle A, Sun W.
    Vaccine; 2008 Jun 02; 26(23):2890-8. PubMed ID: 18448211
    [Abstract] [Full Text] [Related]

  • 3. A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits.
    Kuschner RA, Russell KL, Abuja M, Bauer KM, Faix DJ, Hait H, Henrick J, Jacobs M, Liss A, Lynch JA, Liu Q, Lyons AG, Malik M, Moon JE, Stubbs J, Sun W, Tang D, Towle AC, Walsh DS, Wilkerson D, Adenovirus Vaccine Efficacy Trial Consortium.
    Vaccine; 2013 Jun 19; 31(28):2963-71. PubMed ID: 23623865
    [Abstract] [Full Text] [Related]

  • 4. Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers.
    Dudding BA, Bartelloni PJ, Scott RM, Top FH, Russell PK, Buescher EL.
    Infect Immun; 1972 Mar 19; 5(3):295-9. PubMed ID: 4564559
    [Abstract] [Full Text] [Related]

  • 5. Adenovirus vaccines in the U.S. military.
    Gaydos CA, Gaydos JC.
    Mil Med; 1995 Jun 19; 160(6):300-4. PubMed ID: 7659229
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.
    Natuk RJ, Lubeck MD, Chanda PK, Chengalvala M, Wade MS, Murthy SC, Wilhelm J, Vernon SK, Dheer SK, Mizutani S.
    AIDS Res Hum Retroviruses; 1993 May 19; 9(5):395-404. PubMed ID: 8318268
    [Abstract] [Full Text] [Related]

  • 7. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
    Zhao H, Xu C, Luo X, Wei F, Wang N, Shi H, Ren X.
    Front Immunol; 2018 May 19; 9():335. PubMed ID: 29563911
    [Abstract] [Full Text] [Related]

  • 8. Effects of injectable trace minerals on humoral and cell-mediated immune responses to Bovine viral diarrhea virus, Bovine herpes virus 1 and Bovine respiratory syncytial virus following administration of a modified-live virus vaccine in dairy calves.
    Palomares RA, Hurley DJ, Bittar JH, Saliki JT, Woolums AR, Moliere F, Havenga LJ, Norton NA, Clifton SJ, Sigmund AB, Barber CE, Berger ML, Clark MJ, Fratto MA.
    Vet Immunol Immunopathol; 2016 Oct 01; 178():88-98. PubMed ID: 27496747
    [Abstract] [Full Text] [Related]

  • 9. Live Oral Adenovirus Type 4 and Type 7 Vaccine Induces Durable Antibody Response.
    Collins ND, Adhikari A, Yang Y, Kuschner RA, Karasavvas N, Binn LN, Walls SD, Graf PCF, Myers CA, Jarman RG, Hang J.
    Vaccines (Basel); 2020 Jul 23; 8(3):. PubMed ID: 32718082
    [Abstract] [Full Text] [Related]

  • 10. Generation and characterization of monoclonal antibodies to adenovirus.
    Tuteja U, Batra HV.
    Indian J Exp Biol; 2000 Dec 23; 38(12):1259-62. PubMed ID: 11411051
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, Pfeiffer A, Muellner M, Tauber E, Ramsauer K.
    Lancet; 2019 Dec 22; 392(10165):2718-2727. PubMed ID: 30409443
    [Abstract] [Full Text] [Related]

  • 12. Intranasal vaccination of pigs against Aujeszky's disease: comparison with one or two doses of attenuated vaccines in pigs with high maternal antibody titres.
    Van Oirschot JT.
    Res Vet Sci; 1987 Jan 22; 42(1):12-6. PubMed ID: 3029845
    [Abstract] [Full Text] [Related]

  • 13. A recombinant virus-like particle vaccine against adenovirus-7 induces a potent humoral response.
    Mazboudi R, Mulhall Maasz H, Resch MD, Wen K, Gottlieb P, Alimova A, Khayat R, Collins ND, Kuschner RA, Galarza JM.
    NPJ Vaccines; 2023 Oct 11; 8(1):155. PubMed ID: 37821505
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
    Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, Joshi G, Stanley D, Kunchai M, Eller LA, Bailer RT, Koup RA, Nabel GJ, Mascola JR, Sullivan NJ, Graham BS, Roederer M, Michael NL, Robb ML, Ledgerwood JE, RV 247 Study Team.
    Lancet; 2015 Apr 18; 385(9977):1545-54. PubMed ID: 25540891
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
    Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF, Bhamarapravati N.
    Pediatr Infect Dis J; 2004 Feb 18; 23(2):99-109. PubMed ID: 14872173
    [Abstract] [Full Text] [Related]

  • 16. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX, Hou LH, Meng FY, Wu SP, Hu YM, Liang Q, Chu K, Zhang Z, Xu JJ, Tang R, Wang WJ, Liu P, Hu JL, Luo L, Jiang R, Zhu FC, Chen W.
    Lancet Glob Health; 2017 Mar 18; 5(3):e324-e334. PubMed ID: 28017642
    [Abstract] [Full Text] [Related]

  • 17. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.
    Barrera J, Schutta C, Pisano M, Grubman MJ, Brake DA, Miller T, Kamicker BJ, Olutunmbi F, Ettyreddy D, Brough DE, Butman BT, Neilan JG.
    Vaccine; 2018 Feb 14; 36(8):1078-1084. PubMed ID: 29358056
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
    Hsu KH, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, Mizutani S, Murphy BR, Collins PL, Chanock RM.
    J Infect Dis; 1992 Oct 14; 166(4):769-75. PubMed ID: 1527411
    [Abstract] [Full Text] [Related]

  • 19. Emergence of adenovirus type 14 in US military recruits--a new challenge.
    Binn LN, Sanchez JL, Gaydos JC.
    J Infect Dis; 2007 Nov 15; 196(10):1436-7. PubMed ID: 18008220
    [No Abstract] [Full Text] [Related]

  • 20. Recombinant human adenovirus-5 expressing capsid proteins of Indian vaccine strains of foot-and-mouth disease virus elicits effective antibody response in cattle.
    Sreenivasa BP, Mohapatra JK, Pauszek SJ, Koster M, Dhanya VC, Tamil Selvan RP, Hosamani M, Saravanan P, Basagoudanavar SH, de Los Santos T, Venkataramanan R, Rodriguez LL, Grubman MJ.
    Vet Microbiol; 2017 May 15; 203():196-201. PubMed ID: 28619144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.